CCL Products Q1 FY27 Results Analysis: PAT Jumps 61%, Standalone PAT Falls 29%
CCL Products (India) Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 1,200.45 Cr (+13.72% YoY) and PAT growth of +61.31% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 27, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 1,200.45 Cr (+13.72% YoY) |
| PAT (Q1) | Rs. 116.87 Cr (+61.31% YoY) |
| EBITDA margin | 16.12% (+106 bps YoY) |
| EPS (Q1) | Rs. 8.77 (+60.92% YoY) |
| Market cap | Rs. 15,681.52 Cr |
| CMP | Rs. 1,174.40 |
Quarter Snapshot
CCL Products delivered 13.7% revenue growth and 61.3% PAT growth, with EBITDA margin expanding 106 bps. The Vietnam subsidiary is the profit engine, contributing 81% of group PAT. However, the effective tax rate collapsed to 9.4% (unsustainable) and standalone business PAT fell 28.6% due to high-cost inventory, tempering the quality of earnings.
Key Investment Insights
Key Positives
- Consolidated revenue grew 13.72% YoY to Rs.1,200.45 Cr, led by subsidiary revenue (+19.76% YoY).
- EBITDA grew 21.71% YoY to Rs.193.55 Cr, with margin expanding 106 bps to 16.12%.
- PAT grew 61.31% YoY to Rs.116.87 Cr, driven by operating leverage and lower finance costs (-14.90% YoY).
- Subsidiaries contributed 80.8% of group PAT (from 56.7% a year ago), with Vietnam PAT margin at ~15.9%.
- Finance costs declined 14.90% YoY despite ongoing capex.
Risk Factors
- Effective tax rate collapsed to 9.42% from 23.08% YoY, inflating PAT by ~Rs.18 Cr; normalisation to ~20% would reduce PAT growth to ~40%.
- Standalone PAT declined 28.58% YoY as cost-of-materials ratio surged to 71.75% from 54.50% due to inventory lag.
- Cost of materials ratio (consolidated) increased 649 bps YoY to 67.80%, though this is a temporary inventory-timing effect.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.